Zilucoplan 23mg/0.574ml solution for injection pre-filled syringes
Requires a prescription from a doctor or prescriber
Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Zilucoplan
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Zilucoplan
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
172 hours
Mechanism
The complement system is part of the innate immune system and is critical in inf…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
0.3 mg/k
Half-life
172 hours
[L48516]
Protein binding
99%
[L48516]
Volume of distribution
3.51 L
[L48516]
Metabolism
10%
Elimination
1%
[L48516]
Clearance
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L48516][L49126]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 359 interactions
[L48516]
The exact mechanism of zilucoplan in gMG has not been fully elucidated. Zilucoplan binds to the complement protein C5 with high affinity to inhibit its cleavage to C5a and C5b, preventing the generation of C5b9.[L48516]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L48516]
After daily repeated subcutaneous administration of 0.3 mg/kg zilucoplan, plasma concentrations of zilucoplan were consistent, with steady state trough concentrations being reached by four weeks of treatment with zilucoplan through 12 weeks.
[L48516]
[L48516]
[L48516]
[L48516]
RA102758, formed by protease-mediated degradation, is pharmacologically inactive. The AUCs of both metabolites were approximately 10% of the parent AUC.
[L48516]
[L48516]
Proteins and enzymes this drug interacts with in the body
PMID:12878586 PMID:18204047 PMID:30643019 PMID:6554279
Activated downstream of classical, alternative, lectin and GZMK complement pathways PMID:12878586 PMID:18204047 PMID:30643019 PMID:6554279
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC L04AJ06
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Zilucoplan
Additional database identifiers
Drugs Product Database (DPD)
23936
ChemSpider
71115966
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1331
GenAtlas
C5
GeneCards
C5
GenBank Gene Database
M57729
GenBank Protein Database
179983
UniProt Accession
CO5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2645
GeneCards
CYP4F2
Guide to Pharmacology
1344
UniProt Accession
CP4F2_HUMAN
Patent information
9 active patents
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: